We are live on ! Find out more
Superstring Capital Management

Superstring Capital Management Portfolio holdings

AUM $200M Turnover 47.73%
1-Year Est. Return 216.62%
This Fund
S&P 500
This Quarter Est. Return
-8.23%
1 Year Est. Return
+216.62%
3 Year Est. Return
+1,109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$115M
AUM Growth
+$1.24M
Cap. Flow
+$25.9M
Cap. Flow %
22.42%
Top 10 Hldgs %
67.87%
Holding
48
New
20
Increased
9
Reduced
8
Closed
9
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.3 years
Avg Time Held Equity only
0.3 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.3 years

Top Sells

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$6.2M
2
CAPR icon
Capricor Therapeutics
CAPR
+$4.94M
3
CYTK icon
Cytokinetics
CYTK
+$4.49M
4
ETNB icon
89bio
ETNB
+$3.81M
5
NKTX icon
Nkarta
NKTX
+$3.35M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
2 Miscellaneous 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ORIC icon
1
Oric Pharmaceuticals
ORIC
$815M
$12.8M 11.05%
1,580,745
+631,223
+66% +$5.79M
2024 Q3
1 quarter
TERN icon
2
DELISTED
Terns Pharmaceuticals
TERN
$11.2M 9.69%
2,020,562
+672,016
+50% +$4.55M
2024 Q2
2 quarters
ZLAB icon
3
Zai Lab
ZLAB
$2.93B
$10.6M 9.15%
403,630
-223,302
-36% -$6.2M
2024 Q2
2 quarters
NVCR icon
4
NovoCure
NVCR
$1.38B
$8.55M 7.41%
286,970
-105,741
-27% -$2.24M
2024 Q2
2 quarters
BBIO icon
5
BridgeBio Pharma
BBIO
$15.1B
$7.19M 6.23%
262,141
+35,457
+16% +$916K
2023 Q4
4 quarters
COGT icon
6
Cogent Biosciences
COGT
$4.77B
$7.1M 6.15%
+910,865
New +$9.08M
2024 Q4
0 quarters
CYTK icon
7
Cytokinetics
CYTK
$7.82B
$6.09M 5.27%
129,389
-86,409
-40% -$4.49M
2023 Q4
4 quarters
GPCR icon
8
Structure Therapeutics
GPCR
$1.33B
$5.88M 5.09%
216,811
-10,236
-5% -$363K
2024 Q3
1 quarter
IDYA icon
9
IDEAYA Biosciences
IDYA
$3.08B
$5.84M 5.05%
+227,102
New +$6.43M
2024 Q4
0 quarters
URGN icon
10
UroGen Pharma
URGN
$1.38B
$3.21M 2.78%
+301,206
New +$3.61M
2024 Q4
0 quarters
SMMT icon
11
Summit Therapeutics
SMMT
$9.45B
$2.94M 2.54%
+164,564
New +$3.19M
2024 Q4
0 quarters
TIL icon
12
Instil Bio
TIL
$41.2M
$2.83M 2.45%
148,017
+40,472
+38% +$1.23M
2024 Q3
1 quarter
PTGX icon
13
Protagonist Therapeutics
PTGX
$8.15B
$2.66M 2.3%
+68,892
New +$3M
2024 Q4
0 quarters
INSM icon
14
Insmed
INSM
$27B
$2.48M 2.15%
+35,966
New +$2.59M
2024 Q4
0 quarters
FATE icon
15
Fate Therapeutics
FATE
$156M
$2.28M 1.97%
1,379,556
-87,378
-6% -$220K
2023 Q4
4 quarters
LEGN icon
16
Legend Biotech
LEGN
$3.1B
$2.26M 1.96%
69,594
+9,079
+15% +$376K
2024 Q2
2 quarters
TARA icon
17
Protara Therapeutics
TARA
$156M
$1.9M 1.65%
+360,000
New +$1.16M
2024 Q4
0 quarters
CABA icon
18
Cabaletta Bio
CABA
$239M
$1.87M 1.62%
822,293
+690,498
+524% +$2.42M
2024 Q1
3 quarters
DYN icon
19
Dyne Therapeutics
DYN
$3.13B
$1.72M 1.49%
+73,150
New +$2.16M
2024 Q4
0 quarters
ORIC icon
20
CALL
Oric Pharmaceuticals
ORIC
$815M
$1.61M 1.4%
+200,000
New +$1.84M
2024 Q4
0 quarters
SVRA icon
21
Savara
SVRA
$984M
$1.56M 1.35%
508,338
+308,338
+154% +$1.08M
2023 Q4
4 quarters
TNGX icon
22
Tango Therapeutics
TNGX
$4.32B
$1.47M 1.27%
474,955
-124,093
-21% -$576K
2024 Q2
2 quarters
KURA icon
23
Kura Oncology
KURA
$651M
$1.38M 1.19%
+157,959
New +$2.27M
2024 Q4
0 quarters
INCY icon
24
Incyte
INCY
$24.5B
$1.24M 1.08%
+18,009
New +$1.28M
2024 Q4
0 quarters
ONC icon
25
BeOne Medicines
ONC
$47.6B
$1.18M 1.02%
+6,365
New +$1.3M
2024 Q4
0 quarters

Similar funds

Superstring Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Superstring Capital Management held 48 positions worth $115M, up 1.1% from $114M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Superstring Capital Management deployed $25.9M of net new capital in Q4 2024, opening 20 new positions and adding to 9 existing holdings. Its largest new stake was Cogent Biosciences: 910,865 shares worth $7.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Zai Lab, an estimated $6.2M trimmed.

  • Superstring Capital Management's largest Q4 2024 buy was Cogent Biosciences: 910,865 shares worth $7.1M.
  • Superstring Capital Management added most to Oric Pharmaceuticals in Q4 2024, an estimated $5.79M increase.
  • Superstring Capital Management's biggest Q4 2024 reduction was Zai Lab, cutting an estimated $6.2M.
  • Superstring Capital Management fully exited Nkarta in Q4 2024, selling an estimated $3.35M.
  • Superstring Capital Management's ten largest holdings make up 68% of its $115M portfolio in Q4 2024.
  • Superstring Capital Management opened 20 new positions and closed 9 in Q4 2024.
  • Superstring Capital Management's portfolio value rose 1.1% quarter-over-quarter to $115M.

Based on Superstring Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.